MULTRYS Drug Patent Profile
✉ Email this page to a colleague
When do Multrys patents expire, and when can generic versions of Multrys launch?
Multrys is a drug marketed by Am Regent and is included in one NDA. There is one patent protecting this drug.
This drug has six patent family members in six countries.
The generic ingredient in MULTRYS is cupric sulfate; manganese sulfate; selenious acid; zinc sulfate. One supplier is listed for this compound. Additional details are available on the cupric sulfate; manganese sulfate; selenious acid; zinc sulfate profile page.
DrugPatentWatch® Generic Entry Outlook for Multrys
Multrys was eligible for patent challenges on April 30, 2023.
Indicators of Generic Entry
Summary for MULTRYS
International Patents: | 6 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for MULTRYS |
What excipients (inactive ingredients) are in MULTRYS? | MULTRYS excipients list |
DailyMed Link: | MULTRYS at DailyMed |
Pharmacology for MULTRYS
Drug Class | Copper Absorption Inhibitor Paramagnetic Contrast Agent |
Mechanism of Action | Magnetic Resonance Contrast Activity |
Physiological Effect | Decreased Copper Ion Absorption |
Anatomical Therapeutic Chemical (ATC) Classes for MULTRYS
US Patents and Regulatory Information for MULTRYS
MULTRYS is protected by one US patents and one FDA Regulatory Exclusivity.
Patents protecting MULTRYS
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting MULTRYS
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Am Regent | MULTRYS | cupric sulfate; manganese sulfate; selenious acid; zinc sulfate | SOLUTION;INTRAVENOUS | 209376-003 | Jun 30, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Am Regent | MULTRYS | cupric sulfate; manganese sulfate; selenious acid; zinc sulfate | SOLUTION;INTRAVENOUS | 209376-003 | Jun 30, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for MULTRYS
See the table below for patents covering MULTRYS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20230058047 | 미량 원소 조성물, 그 제조 및 사용 방법 | ⤷ Try a Trial |
Australia | 2021300384 | Trace element compositions, methods of making and use | ⤷ Try a Trial |
China | 116096423 | 微量元素组合物、制备方法及应用 (Microelement composition, preparation method and application) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |